



NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL, OTHER RESTRICTIONS ARE APPLICABLE.
PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS INVESTOR RELATIONS NEWS.

Investor Relations News

Private placement of Evonik shares ahead of listing successfully completed Owners sell additional shares to institutional investors

Essen, 12 March 2013. After the first private placement announced on 22 February 2013, the former sole shareholders of Evonik Industries AG, RAG Foundation and funds advised by CVC Capital Partners, placed further shares with institutional investors. As before, they disposed of equal amounts of shares in a private placement advised by MainFirst Bank AG. This concludes the private placement ahead of the contemplated listing. Overall about 12 per cent of the company's share capital were placed with demand substantially exceeding the number of shares on offer.

The further broadening of the shareholder base marks another step toward the contemplated listing. The new shareholders are selected domestic and international institutional investors. The parties agreed to maintain confidentiality on the purchase price. Now that the private placement is completed, the preparations for a listing of Evonik Industries AG on the Frankfurt stock exchange will continue as scheduled.

"We have met an important requirement for the contemplated listing by successfully completing the private placement," said Werner Mueller, Chairman of the Board of RAG Foundation.

Christian Wildmoser, Partner at CVC, added: "The private placement was met by strong interest from domestic and international investors. We are pleased that today we have taken another step towards making a leading specialty chemicals company accessible to an even broader group of investors."

Klaus Engel, Chairman of the Executive Board of Evonik commented: "We also welcome the new investors among our owners and look forward to working together. We will now move ahead towards the listing together with our owners, marking the next important step in our corporate history."

Not for release, publication or distribution in the United States, Australia, Canada or Japan.

About RAG Foundation

RAG Foundation is a civil-law foundation established in 2007. Its purpose is to build up Foundation assets by 2018 in order to fund long-term liabilities in German coal mining from 2019 onwards. Under the Foundation's Statutes, this objective is to be achieved by means of an initial public offering of Evonik Industries AG.

For further information on the RAG Foundation, please see <http://www.rag-stiftung.de/en/>.

RAG Foundation press contact:
Barbara Müller (Acting Press Officer)
Evonik Industries AG
Phone +49-201-177-3423
Email: barbara.mueller@evonik.com

About CVC Capital Partners

CVC Capital Partners is one of the world's leading private equity and investment advisory firms. Founded in 1981, CVC today employs some 280 people in 21 offices throughout Europe, Asia and the US. CVC has raised over US\$ 44 billion and completed in total over 300 investments. Today, CVC funds are invested in over 60 companies worldwide which employ over 400,000 people and generate combined annual sales of ca. US\$130 billion.

CVC has been operating in Germany since 1986 already. The private equity portfolio in the German speaking region currently consists of three companies in Germany (Evonik, Flint Group, ista) and one in Switzerland (Sunrise). Together, these companies employ close to 50,000 people and generate overall revenues of over €18 billion.

For further information on CVC Capital Partners, please see www.cvc.com.

Michael Iltschev
Hering Schuppener Consulting
Phone +49-69-921874-49
Mobile: +49-151-16231325
E-Mail: miltschev@heringschuppener.com

Dr. Phoebe Kebbel
Hering Schuppener Consulting
Phone +49-69-921874-77
Mobile: +49-173-2862110
E-Mail: pkebbel@heringschuppener.com

About Evonik Industries:

Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik's corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.

Evonik is active in over 100 countries around the world. In fiscal 2012 more than 33,000 employees generated sales of around €13.6 billion and an operating profit (adjusted EBITDA) of about €2.6 billion.

Evonik Industries AG:
Tim Lange
Head of Investor Relations
Phone +49-201-177-3150
E-Mail: tim.lange@evonik.com

Not for release, publication or distribution in the United States, Australia, Canada or Japan.

Disclaimer:

These materials may not be published, distributed or transmitted in the United States, Canada, Australia or Japan. These materials do not constitute an offer of securities for sale or a solicitation of an offer to purchase securities (the "Shares") of Evonik Industries AG (the "Company") in the United States, Germany or any other jurisdiction. The Shares of the Company may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"). The Shares of the Company have not been, and will not be, registered under the Securities Act.

This publication constitutes neither an offer to sell nor a solicitation to buy securities. In the case of a public offering, the offer would be made solely by means of, and on the basis of, a securities prospectus which would have been published. In the case of a public offering, an investment decision regarding any publicly offered securities of Evonik Industries AG should only be made on the basis of the securities prospectus. The securities prospectus would be published promptly upon approval by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin) and would be available free of charge from Evonik Industries AG, Rellinghauser Strasse 1-11, 45128 Essen, Germany, or on the Evonik Industries AG website.

In the United Kingdom, this document is only being distributed to and is only directed at persons who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order") or (ii) are persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations, etc.) (all such persons together being referred to as "Relevant Persons"). This document is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

In so far as forecasts or expectations are expressed in this Investor Relations News or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.